Europska Unija - hrvatski - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastična sredstva - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Europska Unija - hrvatski - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multipli mijelom - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Талидомид - multipli mijelom - imunosupresivi - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

lipomed gmbh - Талидомид - multipli mijelom - imunosupresivi - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

tillomed pharma gmbh, mittelstrasse 5/5a, schonefeld, njemačka - melfalanklorid - prašak i otapalo za otopinu za injekciju / infuziju - 50 mg - urbroj: jedna bočica praška sadrži 50 mg melfalana u obliku melfalanklorida.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pierre fabre medicament - busulfan - transplantacija hematopoetskih matičnih stanica - antineoplastična sredstva - busilvex slijedi ciklofosfamid (bucy2) je indiciran kao uređaj tretman prije konvencionalne matičnih hematopoetskih stanica (hpct) u odraslih bolesnika kada kombinacija se smatra najbolje dostupne opcije. busilvex nakon флударабина (fb) je prikazan kao tretman klima ispred гемопоэтических прогениторных stanica transplantacija (hpct) u odraslih bolesnika koji su kandidati na smanjenje intenziteta klima (rick) način. busilvex zatim ciklofosfamid (bucy4) ili мелфалан (bumel) prikazan je kao tretman klima pred konvencionalnim гемопоэтических прогениторных stanica za transplantaciju mali pacijenti.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - melfalanklorid - prašak i otapalo za otopinu za injekciju / infuziju - 50 mg - urbroj: jedna bočica sadrži 50 mg melfalana (u obliku melfalanklorida)

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - bortezomib - multipli mijelom - drugi antineoplastični agensi - završetak deflacije podržali бортезомиб kao monoterapija ili u kombinaciji s пегилированным липосомальным doksorubicin i дексаметазоном indiciran za liječenje odraslih bolesnika s napreduje multiplog mijeloma, koji je dobio najmanje 1 prije početka terapije i koji su već prošli ili koji nisu prikladni za hematopoetski sustav transplantacije matičnih stanica . završetak deflacije podržali бортезомиб u kombinaciji s мелфаланом i преднизолоном indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne mogu tvrditi da su visoke doze kemoterapije s transplantacije matičnih stanica hematopoetske . završetak deflacije podržali бортезомиб u kombinaciji s дексаметазоном, ili s deksametazona i талидомида je za indukcije liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma, koji imaju pravo na высокодозная kemoterapija s transplantacije matičnih stanica hematopoetske . Бортезомиб završetak deflacije podržali u kombinaciji s rituksimab, ciklofosfamid, doksorubicin i prednizolona indiciran za liječenje odraslih bolesnika s ranije neobrađeni limfoma iz stanica plašt, koji nisu spremni za transplantaciju гемопоэтических matičnih stanica .

Europska Unija - hrvatski - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - busulfan - transplantacija hematopoetskih matičnih stanica - alkilsulfonati - busulfan fresenius kabi slijedi ciklofosfamid (bucy2) je indiciran kao uređaj tretman prije konvencionalne matičnih hematopoetskih stanica (hpct) u odraslih bolesnika kada kombinacija se smatra najbolje dostupne opcije. Бусульфан Фрезениус Каби zatim ciklofosfamid (bucy4) ili мелфалан (bumel) prikazan je kao tretman klima pred konvencionalnim гемопоэтических прогениторных stanica za transplantaciju mali pacijenti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresivi - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).